Ascendis Pharma A/S $ASND Stock Holdings Increased by Sapient Capital LLC

Sapient Capital LLC boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 3.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 95,721 shares of the biotechnology company’s stock after purchasing an additional 3,559 shares during the quarter. Sapient Capital LLC’s holdings in Ascendis Pharma A/S were worth $21,808,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Perceptive Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 41.6% during the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after acquiring an additional 450,000 shares during the period. Fred Alger Management LLC increased its stake in Ascendis Pharma A/S by 106.3% in the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock valued at $75,084,000 after purchasing an additional 181,408 shares in the last quarter. Sei Investments Co. increased its stake in Ascendis Pharma A/S by 24.8% in the 1st quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock valued at $80,318,000 after purchasing an additional 69,673 shares in the last quarter. Pictet Asset Management Holding SA raised its holdings in Ascendis Pharma A/S by 243.0% during the first quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock worth $56,907,000 after purchasing an additional 178,415 shares during the last quarter. Finally, Candriam S.C.A. raised its holdings in Ascendis Pharma A/S by 23.2% during the first quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after purchasing an additional 43,338 shares during the last quarter.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean-Jacques Bienaimé acquired 2,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $246.33 per share, with a total value of $492,660.00. Following the purchase, the director owned 2,900 shares in the company, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 40.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ASND. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, September 25th. HC Wainwright set a $344.00 price objective on Ascendis Pharma A/S in a research report on Thursday, September 10th. Raymond James Financial downgraded Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 price target for the company. in a research report on Tuesday, September 15th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $310.75.

Ascendis Pharma A/S Trading Down 2.5%

Shares of NASDAQ:ASND traded down $5.72 during trading on Thursday, reaching $222.69. The stock had a trading volume of 924,127 shares, compared to its average volume of 704,306. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The stock has a market cap of $13.89 billion, a P/E ratio of 17.28 and a beta of 0.38. The business has a fifty day moving average price of $247.48 and a 200-day moving average price of $242.22. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, analysts anticipate that Ascendis Pharma A/S will post 3.55 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.